Drug intelligence / Profile preview

STR-50

Development stage: Preclinical
Lead developer: Starget Pharma
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

STR-50 is a pan-somatostatin receptor (SSTR) targeting radiopharmaceutical theranostic being developed by Starget Pharma. It is designed for both the diagnostic imaging and therapeutic treatment of neuroendocrine tumors (NET). Unlike many existing SSTR-targeted agents that primarily target the SSTR2 subtype, STR-50 is engineered to bind across multiple SSTR subtypes (pan-SSTR), potentially providing a more comprehensive approach for tumors with heterogeneous receptor expression. The program is currently in the IND-enabling stage of development.

Other names: STR-50 TheranosticSTR50 TheranosticSTR 50 Theranostic

Targets

SSTR3 (Somatostatin receptor 3)

Beyond the preview

Go deeper on STR-50.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STR-50.

Explore the full profile